KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Debt (2016)

Historic Total Debt for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Q4 2016 value amounting to $300.0 million.

  • Vertex Pharmaceuticals' Total Debt rose 164.01% to $300.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $300.0 million, marking a year-over-year increase of 164.01%. This contributed to the annual value of $300.0 million for FY2016, which is 164.01% up from last year.
  • Vertex Pharmaceuticals' Total Debt amounted to $300.0 million in Q4 2016, which was up 164.01% from $297.8 million recorded in Q3 2016.
  • In the past 5 years, Vertex Pharmaceuticals' Total Debt registered a high of $300.0 million during Q4 2016, and its lowest value of $294.7 million during Q3 2014.
  • Over the past 3 years, Vertex Pharmaceuticals' median Total Debt value was $295.0 million (recorded in 2015), while the average stood at $295.9 million.
  • Its Total Debt has fluctuated over the past 5 years, first grew by 3.12% in 2015, then soared by 164.01% in 2016.
  • Over the past 3 years, Vertex Pharmaceuticals' Total Debt (Quarter) stood at $294.8 million in 2014, then rose by 0.13% to $295.2 million in 2015, then increased by 1.64% to $300.0 million in 2016.
  • Its last three reported values are $300.0 million in Q4 2016, $297.8 million for Q3 2016, and $296.5 million during Q2 2016.